Testing and Inspection Technology Platform

1、服务信息（简介）

Canvest Bio provides customized virus clearance process validation services, offering virus detection and titer analysis on samples before and after processing using Q-PCR or infectivity assays to validate the effectiveness of virus removal/inactivation by downstream processes.

Canvest Bio operates a BSL-2 laboratory certified by national authorities and holds both CMA and CNAS certifications for virus clearance process validation. The laboratory is equipped with multiple biosafety cabinets, AKTA purification systems, nanofiltration equipment, ultracentrifuges, and other instruments. These enable virus clearance process validation for various processes, including low pH incubation, heat treatment/pasteurization, S/D treatment, chromatography (affinity chromatography, anion exchange chromatography, hydrophobic chromatography, etc.), and nanomembrane filtration. The company has rich industry experience, having completed hundreds of virus clearance process validation projects.

The director of Canvest Bio’s virus clearance process validation platform holds a Ph.D. in Microbiology from Wuhan University and possesses extensive experience in virology, cell biology, and microbiology, with a focus on cell testing and virus clearance process validation. The professional team has over ten years of industry experience, constantly optimizing technical systems to enhance virus titer and purity to meet regulatory and customer requirements. Core team members have solid backgrounds in biomedical and pharmaceutical fields, with over five years of experience in virus clearance process validation.

In recent years, Canvest Bio has provided virus clearance process validation services to hundreds of domestic and international biopharmaceutical companies. The company considers both domestic and international regulatory requirements, offering comprehensive and reasonable validation plans based on customer needs, along with authoritative testing reports. This has supported companies in process development, new drug clinical trial applications (IND), and biologics license applications (BLA), achieving both positive social and economic impacts.